Billing system transition hits collections and guidance, but AI pathology, acquisitions, and a promising oncology pipeline keep the story alive.
FLGT · Earnings Call · 2026-07-30
An Operational Stumble in the Revenue Engine
Fulgent Genetics' second-quarter report was dominated by a self-inflicted wound: a messy transition of its billing and revenue cycle management system. The company has been upfront about the issue, with CFO Paul Kim acknowledging, “It's just the collection rate that we're using to record revenues. It's been lower than our historical rates.” — Paul Kim, Chief Financial Officer · 2026-07-30 This single problem dragged down revenue recognition, compressed gross margins, and forced a full-year guidance cut from $350M to $330-340M.
What's striking is that this is a collection rate issue, not a demand problem. Volumes remain intact; the revenue cycle transition simply means the company can't bill and collect at its historical pace. The narrative echoes the prior quarter, when management had already noted "timing impact from claims delayed in releasing from processing backlog" (Q1 2026 call) — but the magnitude has escalated. In Q2, Brandon Perthuis, CCO, explained the final phase of the system implementation: “We've identified those features. We're working on implementing those features... we do expect to get back to our historical collection rates in the coming quarters.” — Brandon Perthuis, Chief Commercial Officer · 2026-07-30 The market appears to be buying that recovery: the stock is up 37.9% over the last 90 days, sitting just 7% below its July high.
"Without this issue that Brandon described, we would have reiterated our fiscal year guidance, and Q2 would have been in line with our original expectations." — Paul Kim
Strategic Tailwinds Beyond the Billing Mess
Despite the operational stumble, Fulgent is advancing on multiple strategic fronts that deserve investor attention. The acquisition of Bako Diagnostics and StrataDX — now fully integrated — added $16.9M to revenue in the quarter, helping Anatomic Pathology jump 33% year-over-year. This dovetails with the company's push into AI portfolio expansion in digital pathology, including a novel mast cell quantification algorithm that addresses a long-standing technical challenge. CEO Ming Hsieh highlighted the pipeline momentum, noting on the call: “We have confirmed the end of Phase II meeting with the FDA, which is scheduled later this summer.” — Ming Hsieh, Chief Executive Officer · 2026-07-30 With FID-007 showing encouraging efficacy in head and neck cancer, and FID-022 progressing through dose escalation, the therapeutic development arm is a meaningful optionality.
Yet the company's own history puts the scale in perspective. Revenue peaked at $259M in Q3 2021 and has since roughly halved. The $71M quarterly revenue is a far cry from pandemic-era highs. Gross margins, which once reached 80%, now sit at 30.2% — driven down not only by the RCM issue but also by the loss of a large customer that is moving testing in-house. Paul Kim re-emphasized the customer impact: “Revenue from this customer this quarter decreased $4.6 million from the prior quarter.” — Paul Kim, Chief Financial Officer · 2026-07-30 The company expects the Bako/StrataDX contribution to offset that decline, aided by a newly doubled sales force.
Cash and Conviction
Shareholders have reason to watch the balance sheet. Fulgent ended Q2 with $551.5M in cash and investments, and continues to buy back stock aggressively — over 1.5M shares in Q2 alone, with $75.8M remaining under authorization. The buyback is a signal of confidence, but it also masks the fact that the core lab business is generating negative free cash flow. The company now expects a non-GAAP operating margin in the mid-negative 20% for the full year, a clear admission that fix costs are spread over too thin a revenue base while the RCM issue persists.
Yet there are green shoots. The FID 007 data presented at ASCO, the expansion of the standard of care in carrier screening, and the cross-selling synergies from Bako/StrataDX all suggest the company is positioning for a margin turnaround when the collection rate normalizes. As Brisbane Perthuis noted: "We have proven we can successfully acquire and integrate new assets." That capability, combined with a robust pipeline, is what could take the stock from its current drawdown to a growth trajectory once the billing headaches fade.
In the meantime, investors should watch the guidance revision closely: a full-year revenue cut of ~4% is significant, but the company is fighting on multiple fronts — fixing the RCM, growing the AP business, advancing clinical assets, and managing a $106.1M IRS refund now delayed by constrained IRS resources. The $604M net cash provides substantial runway for the strategic plan.